Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Llewellyn Mills

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Harm Reduction Journal|June 10, 2020
Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)Nicholas Lintzeris, Llewellyn Mills, Anastasia Suraev, et al.
Addiction (Abingdon, England)|July 8, 2023
Identifying thresholds for clinically meaningful change among clients of drug and alcohol services using the Australian Treatment Outcomes ProfileRachel M Deacon, Llewellyn Mills, Raimondo Bruno, et al.
Journal of Cannabis Research|August 16, 2025
Clinicians' attitudes and knowledge of medicinal cannabis in opioid dependence treatment clinics in New South Wales, AustraliaLaila Parvaresh, Llewellyn Mills, Jaleh Gholami, et al.
Drug and Alcohol Dependence Reports|April 25, 2025
Characterizing withdrawal from long-acting injectable buprenorphine: An observational case seriesVictoria Hayes, Llewellyn Mills, Gaye Byron, et al.
Drug and Alcohol Review|May 6, 2025
Clinicians' Perspectives on Cannabis Use and Cannabis Treatment in Clients Undertaking Opioid Dependence TreatmentLaila Parvaresh, Llewellyn Mills, Jaleh Gholami, et al.
Harm Reduction Journal|May 28, 2024
Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022-2023 (CAMS-22)Llewellyn Mills, Jonathon C Arnold, Anastasia Suraev, et al.
Drug and Alcohol Review|March 5, 2020
Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependenceLlewellyn Mills, Nicholas Lintzeris, Raimondo Bruno, et al.
Drug and Alcohol Review|June 30, 2021
Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questionsKristie Mammen, Llewellyn Mills, Rachel M Deacon, et al.
Public Health Genomics|October 4, 2022
Which Test Is Best? A Cluster-Randomized Controlled Trial of a Risk Calculator and Recommendations on Colorectal Cancer Screening Behaviour in General PracticeLyndal J Trevena, Bettina Meiser, Llewellyn Mills, et al.
Drug and Alcohol Dependence|March 22, 2022
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trialMark Montebello, Meryem Jefferies, Llewellyn Mills, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Harm Reduction Journal|June 10, 2020
Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)Nicholas Lintzeris, Llewellyn Mills, Anastasia Suraev, et al.
Addiction (Abingdon, England)|July 8, 2023
Identifying thresholds for clinically meaningful change among clients of drug and alcohol services using the Australian Treatment Outcomes ProfileRachel M Deacon, Llewellyn Mills, Raimondo Bruno, et al.
Journal of Cannabis Research|August 16, 2025
Clinicians' attitudes and knowledge of medicinal cannabis in opioid dependence treatment clinics in New South Wales, AustraliaLaila Parvaresh, Llewellyn Mills, Jaleh Gholami, et al.
Drug and Alcohol Dependence Reports|April 25, 2025
Characterizing withdrawal from long-acting injectable buprenorphine: An observational case seriesVictoria Hayes, Llewellyn Mills, Gaye Byron, et al.
Drug and Alcohol Review|May 6, 2025
Clinicians' Perspectives on Cannabis Use and Cannabis Treatment in Clients Undertaking Opioid Dependence TreatmentLaila Parvaresh, Llewellyn Mills, Jaleh Gholami, et al.
Harm Reduction Journal|May 28, 2024
Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022-2023 (CAMS-22)Llewellyn Mills, Jonathon C Arnold, Anastasia Suraev, et al.
Drug and Alcohol Review|March 5, 2020
Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependenceLlewellyn Mills, Nicholas Lintzeris, Raimondo Bruno, et al.
Drug and Alcohol Review|June 30, 2021
Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questionsKristie Mammen, Llewellyn Mills, Rachel M Deacon, et al.
Public Health Genomics|October 4, 2022
Which Test Is Best? A Cluster-Randomized Controlled Trial of a Risk Calculator and Recommendations on Colorectal Cancer Screening Behaviour in General PracticeLyndal J Trevena, Bettina Meiser, Llewellyn Mills, et al.
Drug and Alcohol Dependence|March 22, 2022
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trialMark Montebello, Meryem Jefferies, Llewellyn Mills, et al.
Pageof 5